Verastem Oncology Inc., of Boston, said it entered an exclusive licensing deal with Paris-based Sanofi SA to develop and commercialize Copiktra (duvelisib), an oral PI3K-delta/gamma inhibitor, for all oncology indications in Russia and CIS, Turkey, the Middle East and Africa. 

Exopharm Ltd., of Melbourne, Australia, said it finalized an AU$4.44 million (US$3.03 million) share placement to new institutional and sophisticated investors. 

Curza Global LLC, of Salt Lake City, received a $5.25 million investment from Novo Holdings Repair Impact Fund to support the advancement of its CZ-02 program that targets multidrug-resistant gram-negative infections.

Alkermes plc, of Dublin, reported second-quarter revenues of $279.9 million compared to $304.6 million for the same period in 2018.

In what it called one of the largest pharmaceutical settlements on behalf of end payers in an antitrust case in the last decade, law firm Hausfeld reported this week that it reached a $55 million settlement with Celgene Corp. in a long-running class action, In re Thalomid and Revlimid Antitrust Litigation. 

Snap Bio Inc., of San Diego, and Torrey Pines Investment (TPI) reported that their joint early drug discovery program within the framework of the i2020 Accelerator has resulted in achieving the projected milestone in developing several small-molecule lead candidates for treatment of hepatocellular carcinoma and hepatoblastoma.